EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Severe Thrombocytopenia Induced by Re‐Exposure to Piperacillin/Tazobactam: A Case Report in Critically Ill Patient With COVID ‐19

Abdullah F. Alharthi, Munirah A. Alkathiri, Othman Alomeir, Shmeylan Al Harbi, Ohoud Aljuhani, Haifa A. Alhaidal, Khalid Al Sulaiman

Clinical Case Reports · 2026-11 · 14 (11)

DOI: 10.1002/ccr3.73787 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Drug‐induced thrombocytopenia is a condition where certain medications can significantly reduce the platelets in the blood. This can increase the risk of bleeding and bruising. We reported a case of a 73‐year‐old woman with multiple comorbidities who was admitted to the hospital with COVID‐19. Upon admission, the patient received multiple antibiotics, including Piperacillin/Tazobactam. In the following days, she developed severe thrombocytopenia upon re‐exposure to Piperacillin/Tazobactam. Other causes of thrombocytopenia were systematically excluded. After discontinuing the Piperacillin/Tazobactam and administering intravenous immunoglobulin (IVIG), the thrombocytopenia resolved. A Naranjo Adverse Drug Reaction Probability Scale score was calculated and indicated a probable (i.e., 6 points) adverse drug reaction. This case underscores the importance of considering Piperacillin/Tazobactam as a potential cause of severe thrombocytopenia in critically ill patients, even in the presence of confounding factors such as COVID‐19. To our knowledge, this is a rarely reported presentation in a patient with a recent COVID‐19 infection. Further studies are needed to clarify the relationship between COVID‐19 and drug‐induced thrombocytopenia.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →